Transaction DateRecipientSharesTypePriceValue
26th May 2020Gail K Naughton426,526Other acquisition or disposition$0.00
26th May 2020Jonathan Jackson2,356,597Other acquisition or disposition$0.00
26th May 2020Martin Latterich11,951Other acquisition or disposition$0.00
26th May 2020Yizhuo Zhang600,983Other acquisition or disposition$0.00
26th May 2020Stephen Chang14,485Other acquisition or disposition$0.00
26th May 2020Brian Satz1,434Other acquisition or disposition$0.00
22nd May 2020Alfred P. Spada12,960Payment by withholding$0.56$7,257.60
22nd May 2020Steven J Mento65,000Exercise of derivative$0.00
22nd May 2020Steven J Mento31,428Payment by withholding$0.56$17,599.68
22nd May 2020Alfred P. Spada31,343Exercise of derivative$0.00
Conatus Pharmaceuticals
Conatus Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Conatus Pharmaceuticals, Inc. focuses in development of emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005.


Ticker: CNAT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1383701
Employees: 6
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals